Healthcare Cabinet Regular Meetings 2018

Meeting Type:      Regular Meeting
Meeting Date:      Tuesday, February 13, 2018
Meeting Location:  State Capitol Room 310
Meeting Time:        9:00 A.M.- 12:00 P.M.
Meeting Agenda:
Meeting Materials: 

 

Meeting Type:        Regular Meeting
Meeting Date:        Tuesday, January 16, 2018
Meeting Location: State Capitol Room 310
Meeting Time:        9:00 A.M. -12:00 P.M.
Meeting Agenda:     1/16/2018
Meeting Materials: 

Public Comment on Draft Recommendations on Pharmaceutical Costs

 

Over the last year the Cabinet has engaged a variety of stakeholders including industry experts, government leaders, researchers, consumers, providers, health plans and advocates, to help the identify a set of detailed recommendations to address pharmaceutical costs. The draft report of recommendations represents the combined efforts of various workgroups and Cabinet discussion. After initial review and consideration of the recommendations of each workgroup, the Cabinet directed the workgroup chairs to collaborate to prioritize the recommendations and combine them into one report to present to the public for comment.  Recommendations are organized into two categories; those that require legislation and those that can be implemented using existing administrative authority. 

 

After public feedback has been collected, the Cabinet will again consider the recommendations at its January 16, 2018 meeting and may change and reprioritize the list prior to sending a final report to the Governor and the legislature for consideration.

 

Written public comment will be accepted until January 15, 2018 at 4:30 p.m. Comments should be sent to Victoria Veltri, Chief Health Policy Advisor, at victoria.veltri@ct.gov.  

 All comments will be posted on the Cabinet website with the January 16th meeting materials.

 

Public Comment on Draft Report


Cabinet Rx Comments

 

Draft Report:  Recommendations on Pharmaceutical Costs

 

High Cost of USA Prescription Drugs                      Velandy Manohar Comments

Healthcare Comments                                               Stephen Smith Comments

Comments of Planned Parenthood    
                     
National Association of Social Workers Comments

Sanofi Comments                                                    Velandy Manohar Response            

Consolidated Comments                                         Ross Kristal Comments

Linda Bronstein Comments                                    PhRMA Comments

Burton and Patricia Conway                                   SIM Comments

Susan Israel Comments                                             Susan Israel Additional Comment

Choosing Wisely Comments                                    Choosing Wisely Basic Information

CMS Comments                                                     BIO Comments

Pfizer Comments                                                   Supriyo Chatterjee Comments

Kathy Flaherty Comments                           Association for Accessible Medicine Comments

CAB Comments                                          Patients for Affordable Drugs Comments

PCMA Comments                                       Lesley Bennett Comments

Epilepsy Foundation Comments                 Public Citizen Comments

Legal Services Comments.                         UHCF Comments